Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onercept maintenance and extended therapy in moderate to severe plaque psoriasis
2004-000535-29Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Aug 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of onercept in plaque psoriasis (5 arms), sponsored by Merck Serono. Primary endpoint: Time to relapse. Started Aug 2004; status: completed.
02
Drugs
onercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2004-000535-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000535-29.